Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D09MJO
|
||||
| Former ID |
DIB001080
|
||||
| Drug Name |
HL-004
|
||||
| Synonyms |
TS-962
|
||||
| Indication | Arteriosclerosis [ICD9: 440; ICD10:I70] | Preclinical | [1] | ||
| Company |
Taisho Pharmaceutical Co Ltd
|
||||
| Structure |
|
Download2D MOL |
|||
| Canonical SMILES |
c1(c(C(C)C)cccc1C(C)C)NC(=O)CSCCCCCCCCCCCCCC
|
||||
| CAS Number |
CAS 144288-97-1
|
||||
| Target and Pathway | |||||
| Target(s) | Liver carboxylesterase | Target Info | Modulator | [2] | |
| KEGG Pathway | Drug metabolism - other enzymes | ||||
| Metabolic pathways | |||||
| Pathway Interaction Database | E2F transcription factor network | ||||
| WikiPathways | NRF2 pathway | ||||
| Nuclear Receptors Meta-Pathway | |||||
| Heroin metabolism | |||||
| Irinotecan Pathway | |||||
| Fluoropyrimidine Activity | |||||
| Phase I biotransformations, non P450 | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033616) | ||||
| REF 2 | ACAT inhibitor HL-004 accelerates the regression of hypercholesterolemia in stroke-prone spontaneously hypertensive rats (SHRSP): stimulation of bile acid production by HL-004. Atherosclerosis. 1997 Aug;133(1):97-104. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.